International Journal of Clinical Oncology

, Volume 15, Issue 2, pp 215–219

Hepatosplenic αβ T cell lymphoma

Authors

  • Yuya Nagai
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Kazuhiro Ikegame
    • Division of Hematology, Department of Internal MedicineHyogo Medical College
  • Minako Mori
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Daichi Inoue
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Takaharu Kimura
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Sonoko Shimoji
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Katsuhiro Togami
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Sumie Tabata
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Masayuki Kurata
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Yukihiro Imai
    • Department of Clinical PathologyKobe City Medical Center General Hospital
  • Akiko Matsushita
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Kenichi Nagai
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
  • Hiroyasu Ogawa
    • Division of Hematology, Department of Internal MedicineHyogo Medical College
    • Department of Hematology and Clinical ImmunologyKobe City Medical Center General Hospital
Case Report

DOI: 10.1007/s10147-010-0028-y

Cite this article as:
Nagai, Y., Ikegame, K., Mori, M. et al. Int J Clin Oncol (2010) 15: 215. doi:10.1007/s10147-010-0028-y

Abstract

A 32-year-old male with chronic hepatitis B was admitted to a hospital with cellulitis in the right leg in September 2006. Pancytopenia, hepatosplenomegaly, and systemic superficial lymph node swelling were noted, and he was referred to our hospital. He developed fever and liver dysfunction in June 2007 and underwent a splenectomy. His pancytopenia subsequently improved. A pathologic diagnosis of hepatosplenic αβ T cell lymphoma was made by examining spleen tissue and biopsy specimens of the liver and mesenteric lymph node. He had stage IVB disease because neoplastic T cells were noted in the bone marrow. The response of the lymphoma to conventional chemotherapy including the CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) and DeVIC (dexamethasone, etoposide, ifoshamide, carboplatin) regimens was poor and transient. A partial remission was obtained with an ESHAP (etoposide, cisplatin, cytarabine, methylprednisolone) regimen. Therefore, we planned a bone marrow transplantation (BMT) from an HLA-haploidentical sibling donor. He was moved to the Department of Hematology, Hyogo Medical College, to receive this BMT as part of a clinical trial. During the conditioning procedure for the transplantation, however, he died of septicemia. Since hepatosplenic αβ T cell lymphoma is very rare with only 23 reported cases to date, herein we report this case and discuss the therapeutic strategy.

Keywords

Hepatosplenic T cell lymphomaAlpha-beta T cellAllogeneic hematopoietic stem cell transplantation

Copyright information

© Japan Society of Clinical Oncology 2010